Drug Class Review on Angiotensin II Receptor Antagonists

The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports.

[1]  C. Vigorito,et al.  Irbesartan Effects on Renal Function in Patients with Renal Impairment and Hypertension: A Drug‐Withdrawal Study , 2001, Journal of cardiovascular pharmacology.

[2]  S. Kjeldsen,et al.  The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity , 1996, Journal of hypertension.

[3]  M. Pfeffer,et al.  Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme , 2005, European journal of heart failure.

[4]  K. Stumpe,et al.  Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist , 2001, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[5]  M. Bilsker,et al.  Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. , 1999, Journal of the American College of Cardiology.

[6]  N. Awan,et al.  A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group. , 2000, International journal of clinical practice.

[7]  N. Rodger,et al.  The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial , 1999 .

[8]  C. Sweet,et al.  Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. , 1995, The American journal of cardiology.

[9]  B. Williams,et al.  Angiotensin II antagonists for hypertension: are there differences in efficacy? , 2000, American journal of hypertension.

[10]  G. Remuzzi,et al.  Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. , 2003, Kidney international.

[11]  L. Wilton,et al.  The safety of valsartan: results of a postmarketing surveillance study on 12 881 patients in England , 2002, Journal of Human Hypertension.

[12]  A. Laucevičius,et al.  An Open-Label Study Investigating the Efficacy and Safety of 12–96 Weeks of Telmisartan Treatment in Patients with Hypertension , 2003, The Journal of international medical research.

[13]  The effects of replacing dihydropyridine calcium‐channel blockers with angiotensin II receptor blocker on the quality of life of hypertensive patients , 2003, Blood pressure. Supplement.

[14]  W. Kraus,et al.  Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. , 2001, Clinical therapeutics.

[15]  M. Nieminen,et al.  The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. , 1997, American journal of hypertension.

[16]  M. D. Rosa,et al.  Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients , 2002, Journal of Human Hypertension.

[17]  D. de Zeeuw,et al.  Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? , 1994, Kidney international.

[18]  Y. Lacourciére.  A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension. , 2000, Clinical therapeutics.

[19]  R. Dal-Ré,et al.  Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. , 1999, Journal of hypertension.

[20]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[21]  H. Diener,et al.  Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES) , 2005, Stroke.

[22]  R. McKelvie,et al.  Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. , 1997, Journal of the American College of Cardiology.

[23]  Y. Lacourciére.  THE INCIDENCE OF COUGH: A COMPARISON OF LISINOPRIL, PLACEBO AND TELMISARTAN, A NOVEL ANGIOTENSIN II ANTAGONIST , 1999, International journal of clinical practice.

[24]  B. Tomlinson,et al.  Double‐Blind Comparison of Losartan, Lisinopril, and Metolazone in Elderly Hypertensive Patients with Previous Angiotensin‐Converting Enzyme Inhibitor‐Induced Cough , 1997, Journal of clinical pharmacology.

[25]  M. Nieminen,et al.  Effects of Losartan or Atenolol in Hypertensive Patients without Clinically Evident Vascular Disease: A Substudy of the LIFE Randomized Trial , 2003, Annals of Internal Medicine.

[26]  B. Trimarco,et al.  Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. , 1999, Current medical research and opinion.

[27]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[28]  B. Grabensee,et al.  Treatment with the angiotensin II antagonist valsartan in patients with chronic renal failure and hypertension. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  B. Brenner,et al.  The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. , 2003, Kidney international.

[30]  A. Bremner,et al.  Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. , 1997, Clinical and experimental hypertension.

[31]  B. Jelaković,et al.  Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. , 2000, Clinical therapeutics.

[32]  P. Petr,et al.  Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. , 1999, Circulation.

[33]  S. Solomon,et al.  Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low–Left Ventricular Ejection Fraction Trials , 2004, Circulation.

[34]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[35]  B. Rutkowski,et al.  Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  J. Patel,et al.  Patients of Southern Asian descent treated with valsartan (POSATIV) study , 2002 .

[37]  D. Mancini,et al.  Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. , 1999, Circulation.

[38]  R. Toto,et al.  Efficacy and Tolerability of Losartan in Hypertensive Patients With Renal Impairment , 1998 .

[39]  P. Zucchelli,et al.  Comparison of losartan and amlodipine in renally impaired hypertensive patients. , 1998, Kidney international. Supplement.

[40]  G. Bakris,et al.  Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. , 2003, American journal of hypertension.

[41]  J. Vítovec,et al.  A comparison of intervention with losartan or captopril in acute myocardial infarction , 2000, European journal of heart failure.

[42]  T. Meinicke,et al.  Long-term Efficacy and Tolerability of Telmisartan as Monotherapy and in Combination with Other Antihypertensive Medications , 2001, Blood pressure.

[43]  T. Marbury,et al.  Long-term safety and antihypertensive efficacy of irbesartan: pooled results of five open-label studies. , 1999, Clinical and experimental hypertension.

[44]  P. Toutouzas,et al.  Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Multicentre Cough Study Group. , 2000, American journal of hypertension.

[45]  G. Bakris,et al.  ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. , 2000, Kidney international.

[46]  C. Sweet,et al.  Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors , 1995, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[47]  S. Solomon,et al.  Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. , 2004, European heart journal.

[48]  R. Fogari,et al.  Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. , 2001, American journal of hypertension.

[49]  S. Oparil,et al.  Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. , 1999, American journal of therapeutics.

[50]  M. S. Nouh,et al.  Efficacy and tolerability of valsartan in patients with mild to moderate essential hypertension. , 2002, Saudi medical journal.

[51]  J. Cohn,et al.  Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT). , 2004, American heart journal.

[52]  Bertram Pitt,et al.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.

[53]  R. Preston,et al.  Comparative Effects on Dynamic Renal Potassium Excretion of ACE Inhibition versus Angiotensin Receptor Blockade in Hypertensive Patients with Type II Diabetes Mellitus , 2002, Journal of clinical pharmacology.

[54]  Y. Lacourciére,et al.  Modulation of the renin-angiotensin-aldosterone system and cough. , 1995, The Canadian journal of cardiology.

[55]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[56]  J. Mallion,et al.  Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension. , 1996, Blood pressure. Supplement.

[57]  Seoung Woo Lee,et al.  Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy. , 2003, Yonsei medical journal.

[58]  C. Helmers,et al.  Safety and efficacy of valsartan versus enalapril in heart failure patients. , 2002, International Journal of Cardiology.

[59]  P. Palatini,et al.  A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. , 2003, Clinical therapeutics.

[60]  B. Brenner,et al.  Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study. , 2004, Diabetes care.

[61]  S. Nielsen,et al.  Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[62]  A. Ducharme,et al.  Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure. , 2005, American heart journal.

[63]  T. Kahan,et al.  Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. , 2000, American journal of hypertension.

[64]  M. Lehtovirta,et al.  Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes. , 1998, Blood pressure.

[65]  F. Coe,et al.  Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. , 1999, Kidney International.

[66]  B. Karlberg,et al.  Effects of modulators of the renin—angiotensin—aldosterone system on cough , 1994, Journal of hypertension.

[67]  D. Snavely,et al.  Use of losartan in the treatment of hypertensive patients with a history of cough induced by angiotensin-converting enzyme inhibitors. , 1998, Clinical therapeutics.

[68]  S. Yusuf,et al.  Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. , 1999, Circulation.

[69]  K. Dickstein,et al.  Effects of losartan and captopril on mortality and morbidity after acute myocardial infarction: The OPTIMAAL randomized trial. , 2002 .

[70]  J. Laragh,et al.  Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial , 2004, The Lancet.

[71]  A. Zanchetti,et al.  Cognitive Function and Health-Related Quality of Life in Elderly Patients with Hypertension - Baseline Data from the Study on COgnition and Prognosis in the Elderly (SCOPE) , 2002, Blood pressure.

[72]  M. Pfeffer,et al.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. , 1999, Journal of cardiac failure.

[73]  H. Parving,et al.  Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[74]  E. Lewis,et al.  The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[75]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[76]  E. Michelson,et al.  Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. , 2001, The American journal of cardiology.

[77]  K. Dickstein,et al.  Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. , 1999, The American journal of cardiology.

[78]  B. Karlberg,et al.  Long-term Exposure to Telmisartan as Monotherapy or Combination Therapy: Efficacy and Safety , 2002, Blood pressure.

[79]  M. Cooper,et al.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study , 2000, BMJ : British Medical Journal.

[80]  W. Elliott.  Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients , 1999, Journal of Human Hypertension.

[81]  T. Saruta,et al.  Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease , 2003, Journal of Human Hypertension.

[82]  E. Breeze,et al.  Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo , 2001, Journal of Human Hypertension.

[83]  A. Parkhomenko,et al.  Additional effects of irbesartan when compared to captopril in the prevention of post-infarction left ventricular dilatation. , 2002, Acta cardiologica.

[84]  H. Gavras,et al.  Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. , 1999, Current medical research and opinion.

[85]  S. Neldam,et al.  Antihypertensive Treatment in Elderly Patients Aged 75 Years or Over , 2001, Drugs & aging.

[86]  M. Nieminen,et al.  Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. , 1998, Hypertension.

[87]  B. Prichard,et al.  Eprosartan versus Enalapril in Elderly Patients with Hypertension: a Doubleblind, Randomized Trial , 2001, Blood pressure.

[88]  E. O’Brien,et al.  Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorathiazide ‐ a randomized controlled trial , 2000, Journal of hypertension.

[89]  J. Stangier,et al.  The Effect of Telmisartan on the Steady‐State Pharmacokinetics of Digoxin in Healthy Male Volunteers , 2000, Journal of clinical pharmacology.

[90]  J. Rosenstock,et al.  The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non‐responsive to hydrochlorothiazide alone , 1998, Journal of clinical pharmacy and therapeutics.

[91]  J. McGill,et al.  Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension , 2001, Clinical cardiology.

[92]  A. Hofman,et al.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.

[93]  R. Torella,et al.  Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study. , 2002, Diabetes care.

[94]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[95]  M. Pfeffer,et al.  Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. , 2000, American heart journal.

[96]  H. Morita,et al.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. , 2003, Lancet.

[97]  C Hall,et al.  Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. , 1995, Journal of the American College of Cardiology.

[98]  P. Raskin,et al.  The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide , 1999, Journal of Human Hypertension.

[99]  M. Adachi,et al.  Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[100]  B. Dahlof,et al.  Cardiovascular morbidity and mortality in the losartan intervention for end point reduction in hypertension study (LIFE): a randomised trial against atenolol☆ , 2002 .

[101]  R. Fogari,et al.  Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men , 2002, European Journal of Clinical Pharmacology.

[102]  C. Erem,et al.  The effects of losartan and fosinopril in hypertensive type 2 diabetic patients. , 2002, Diabetes research and clinical practice.

[103]  G. Pylypchuk.  ACE Inhibitor—Versus Angiotensin II Blocker–Induced Cough and Angioedema , 1998, The Annals of pharmacotherapy.

[104]  P. Pentikäinen,et al.  Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well‐being , 1997, Journal of hypertension.

[105]  H. Brunner.  Clinical efficacy and tolerability of olmesartan. , 2004, Clinical therapeutics.

[106]  J. Kleijnen,et al.  Systematic Review: Antihypertensive Drug Therapy in Black Patients , 2004, Annals of Internal Medicine.

[107]  Charles E. McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[108]  M. Weir,et al.  Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. , 2001, American journal of hypertension.

[109]  J. Mustonen,et al.  Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. , 2004, The New England journal of medicine.

[110]  A. Berghold,et al.  Angiotensin receptor blockers as anti‐hypertensive treatment for patients with diabetes mellitus: meta‐analysis of controlled double‐blind randomized trials , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[111]  M. Böhm,et al.  Safety and Tolerability of Eprosartan in Combination with Hydrochlorothiazide , 2002, Drug safety.

[112]  D. Armaganijan,et al.  Valsartan alone and as part of combination therapy in general practice in Brazil. , 2001, International journal of clinical practice.

[113]  H. Parving,et al.  Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. , 2003, Diabetes care.

[114]  J. Edelman,et al.  Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. , 1996, Clinical therapeutics.

[115]  S. Umemura,et al.  Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension--a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.

[116]  J. Neutel,et al.  Efficacy of valsartan in patients aged > or =65 years with systolic hypertension. , 2000, Clinical therapeutics.

[117]  R. Davies,et al.  Safety of irbesartan in the treatment of mild to moderate systemic hypertension. , 1998, The American journal of cardiology.

[118]  F. Luft,et al.  Effect of valsartan on renal function in patients with hypertension and stable renal insufficiency , 1999 .

[119]  N. Perico,et al.  Efficacy and Tolerability of Valsartan Compared with Lisinopril in Patients with Hypertension and Renal Insufficiency , 1997 .

[120]  P. Dunselman.  Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. , 2001, International journal of cardiology.

[121]  S. Nesbitt,et al.  Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. , 2004, Journal of the American College of Cardiology.

[122]  A. Sharma,et al.  Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. , 2005, Clinical nephrology.

[123]  M. Fischer,et al.  Efficacy and Tolerability of Candesartan Cilexetil Monotherapy or in Combination with Other Antihypertensive Drugs , 1999 .

[124]  J. Rouleau,et al.  The OPTIMAAL study, not so optimal: the lessons of LIFE, RENAAL and IDNT. , 2003, Canadian Journal of Cardiology.

[125]  R. Saracho,et al.  Evaluation of the Losartan in Hemodialysis (ELHE) Study. , 1998, Kidney international. Supplement.

[126]  G. Müller,et al.  A randomized, double-blind, parallel study on the safety and antihypertensive efficacy of losartan compared to captopril in patients with mild to moderate hypertension and impaired renal function. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[127]  M. Burnier,et al.  Angiotensin II receptor antagonists , 2000, The Lancet.

[128]  H. Diener,et al.  The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors , 2003, Stroke.

[129]  T. Ogihara,et al.  Clinical efficacy and tolerability of candesartan cilexetil , 1999, Journal of Human Hypertension.

[130]  L. Ramsay,et al.  Double-blind comparison of losartan, lisinopril and hydrochlorothiazide in hypertensive patients with a previous angiotensin converting enzyme inhibitor-associated cough , 1995, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[131]  D. de Zeeuw,et al.  Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. , 1994, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[132]  R. McKelvie,et al.  Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. , 2002, Journal of the American College of Cardiology.

[133]  A. Hofman,et al.  Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE) , 2004, Journal of Human Hypertension.

[134]  M. Nieminen,et al.  Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. , 2002, JAMA.

[135]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[136]  D. Kitzman,et al.  Effect of Candesartan and Verapamil on Exercise Tolerance in Diastolic Dysfunction , 2004, Journal of cardiovascular pharmacology.

[137]  P. Kincaid‐smith,et al.  Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[138]  N. Leidy,et al.  Psychometric properties of the VSQLQ in black patients with mild hypertension. Vital Signs Quality of Life Questionnaire. , 2000, Journal of the National Medical Association.

[139]  D. Murdoch,et al.  ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. , 2001, American heart journal.

[140]  G. Mayer,et al.  The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[141]  J. Neutel,et al.  Evaluation of Angiotensin II Receptor Blockers for 24‐Hour Blood Pressure Control: Meta‐Analysis of a Clinical Database , 2003, Journal of clinical hypertension.

[142]  E. Michelson,et al.  Effects of candesartan cilexetil on health-related quality of life in black patients with systemic hypertension in the ABC Trial. , 2000, Heart disease.

[143]  E. Erdmann,et al.  The safety and tolerability of candesartan cilexetil in CHF , 2000 .

[144]  H. Parving,et al.  Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. , 2002, Diabetes care.

[145]  S. Kjeldsen,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The value randomised trial☆ , 2004 .

[146]  H. Parving,et al.  Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. , 2003, Journal of the American Society of Nephrology : JASN.

[147]  A. Hartmann,et al.  Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[148]  Teven,et al.  EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .

[149]  K. Okumura,et al.  Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. , 2003, American heart journal.

[150]  Trefor Owen Morgan,et al.  A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension. , 2002, American journal of hypertension.

[151]  G. Braunstein,et al.  Meta-Analysis: Angiotensin-Receptor Blockers in Chronic Heart Failure and High-Risk Acute Myocardial Infarction , 2004, Annals of Internal Medicine.

[152]  H. Parving,et al.  Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. , 2000, Kidney international.

[153]  K. Dickstein,et al.  Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan. , 2001, The American journal of cardiology.

[154]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[155]  K. Dickstein,et al.  Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II. , 1999, Journal of cardiac failure.

[156]  P. Seferovic,et al.  Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure. , 2003, American heart journal.

[157]  P. Sever,et al.  Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. , 1997, Journal of human hypertension.

[158]  S. Ross,et al.  Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. , 2000, Kidney international.

[159]  M. Burnier,et al.  Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients , 1998, Journal of hypertension.

[160]  A. Cowley,et al.  Haemodynamic, neurohumoral and exercise effects of losartan vs. captopril in chronic heart failure: results of an ELITE trial substudy , 1999, European journal of heart failure.

[161]  S. Yusuf,et al.  Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. , 1997, The Canadian journal of cardiology.

[162]  J. Schrader,et al.  Hypertension and stroke – rationale behind the ACCESS trial , 1998, Basic Research in Cardiology.

[163]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[164]  H. Parving,et al.  Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. , 2003, Diabetes care.

[165]  H. Parving,et al.  Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. , 2003, Kidney international.

[166]  D. Kitzman,et al.  Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. , 1999, Journal of the American College of Cardiology.

[167]  A. Hofman,et al.  Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). , 2004, Journal of the American College of Cardiology.

[168]  A. Matsumori.  Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure , 2003, European journal of heart failure.

[169]  M. Goicoechea,et al.  Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. , 2002, Kidney international. Supplement.

[170]  T. Saruta,et al.  Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis , 2002, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[171]  N. Rodger,et al.  THE EFFECT OF VALSARTAN AND CAPTOPRIL ON LIPID PARAMETERS IN PATIENTS WITH TYPE II DIABETES MELLITUS AND NEPHROPATHY , 1999, International journal of clinical practice.

[172]  C. Ferrario,et al.  Sexual Dysfunction in Hypertensive Patients Treated with Losartan , 2001, The American journal of the medical sciences.

[173]  M. Burnier,et al.  Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout , 2001, Journal of hypertension.

[174]  A. Hofman,et al.  The Study on COgnition and Prognosis in the Elderly (SCOPE) – Major CV events and stroke in subgroups of patients , 2005, Blood pressure.

[175]  I. Ebihara,et al.  Comparison between the Angiotensin II Receptor Antagonist Candesartan Cilexetil and the Angiotensin-Converting Enzyme Inhibitor Trandolapril in Microalbuminuria of Patients with Early Diabetic Nephropathy , 2000, Nephron.

[176]  W A Ray,et al.  Black Americans have an increased rate of angiotensin converting enzyme inhibitor‐associated angioedema , 1996, Clinical pharmacology and therapeutics.

[177]  W. Keane,et al.  Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[178]  B. Levine,et al.  Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. , 1999, Current medical research and opinion.

[179]  Hiroshi Tanaka,et al.  Effects of Candesartan on Cough and Bronchial Hyperresponsiveness in Mildly to Moderately Hypertensive Patients With Symptomatic Asthma , 2001, Circulation.

[180]  D. Wheeler.  Should hyperlipidaemia in dialysis patients be treated? , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[181]  B. Grabensee,et al.  Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. , 1998, Journal of the American Society of Nephrology : JASN.

[182]  D. Iarussi,et al.  Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. , 1999, American journal of hypertension.

[183]  J. Cohn,et al.  Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. , 2002, Journal of the American College of Cardiology.

[184]  J. Edelman,et al.  Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. , 1995, Clinical therapeutics.

[185]  D. Jorkasky,et al.  The Effects of Eprosartan, an Angiotensin II AT1 Receptor Antagonist, on Uric Acid Excretion in Patients with Mild to Moderate Essential Hypertension , 1998, Journal of clinical pharmacology.

[186]  S. Oparil,et al.  Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. , 1996, Clinical therapeutics.

[187]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[188]  E. Breeze,et al.  Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension , 2001, Journal of Human Hypertension.

[189]  M. Pfeffer,et al.  Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy , 2003, Annals of Internal Medicine.

[190]  M. Buyse,et al.  Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group. , 2000, The American journal of cardiology.

[191]  D. de Zeeuw,et al.  Effect of Losartan on Microalbuminuria in Normotensive Patients with Type 2 Diabetes Mellitus , 2003, Annals of Internal Medicine.

[192]  M. Hanefeld,et al.  Effect of the Angiotensin II Receptor Antagonist Valsartan on Lipid Profile and Glucose Metabolism in Patients with Hypertension , 2001, The Journal of international medical research.

[193]  L. Dworkin,et al.  Incidence of hyperkalemia in high risk patients during treatment with an angiotensin converting enzyme inhibitor (Lisinopril) versus an angiotensin II receptor blocker (Losartan). , 2004, South Dakota journal of medicine.

[194]  J. Laragh,et al.  VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk , 2003 .

[195]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[196]  M. Kurabayashi,et al.  Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[197]  Marvin Zelen,et al.  The analysis of several 2× 2 contingency tables , 1971 .

[198]  M. Schluchter,et al.  The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) , 2000, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[199]  P. Raskin,et al.  Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. , 1998, American journal of hypertension.

[200]  L. Ruilope,et al.  AT1 blockers and uric acid metabolism: are there relevant differences? , 2002, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[201]  D. Henry,et al.  Valsartan, a New Angiotensin II Receptor Antagonist: A Double‐Blind Study Comparing the Incidence of Cough with Lisinopril and Hydrochlorothiazide , 1997, Journal of clinical pharmacology.

[202]  M. Pfeffer,et al.  Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. , 2000, American heart journal.

[203]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[204]  N. Santanello,et al.  Randomised comparison of losartan vs. captopril on quality of life in elderly patients with symptomatic heart failure: The losartan heart failure ELITE quality of life substudy , 2004, Quality of Life Research.